Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
Standard
Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? / Petersen, Jorg; Dandri-Petersen, Maura.
In: LIVER INT, Vol. 35 Suppl 1, 01.2015, p. 114-20.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
AU - Petersen, Jorg
AU - Dandri-Petersen, Maura
N1 - © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2015/1
Y1 - 2015/1
N2 - Currently available antiviral treatment for chronic hepatitis B can be divided into two classes of therapeutic agents: pegylated interferon alpha (PEG-IFN) and nucleos(t)ide analogues (NAs). The major advantages of NAs are good tolerance and potent antiviral activity associated with high rates of on-treatment response to therapy. The advantages of PEG-IFN include a finite course of treatment, the absence of drug resistance, and an opportunity to obtain a durable post-treatment response to therapy. The use of these two antiviral agents with different mechanisms of action in combination is theoretically an attractive approach for treatment, either simultaneously, as sequential combination therapy (add-on), or even as an immediate switch from one agent to the other. Different NAs have also been combined in certain clinical situations. At present, several studies have confirmed certain virological advantages to combination therapies, but pivotal prospective studies demonstrating long-term clinical benefit to patients are still missing. Therefore, combination treatment, especially with PEG-IFN plus NAs, is not indicated and was not recommended by the European Association for the Study of the Liver Clinical Practice Guidelines written in 2012, while the guidelines for the use of combination NAs is limited to very few clinical situations.
AB - Currently available antiviral treatment for chronic hepatitis B can be divided into two classes of therapeutic agents: pegylated interferon alpha (PEG-IFN) and nucleos(t)ide analogues (NAs). The major advantages of NAs are good tolerance and potent antiviral activity associated with high rates of on-treatment response to therapy. The advantages of PEG-IFN include a finite course of treatment, the absence of drug resistance, and an opportunity to obtain a durable post-treatment response to therapy. The use of these two antiviral agents with different mechanisms of action in combination is theoretically an attractive approach for treatment, either simultaneously, as sequential combination therapy (add-on), or even as an immediate switch from one agent to the other. Different NAs have also been combined in certain clinical situations. At present, several studies have confirmed certain virological advantages to combination therapies, but pivotal prospective studies demonstrating long-term clinical benefit to patients are still missing. Therefore, combination treatment, especially with PEG-IFN plus NAs, is not indicated and was not recommended by the European Association for the Study of the Liver Clinical Practice Guidelines written in 2012, while the guidelines for the use of combination NAs is limited to very few clinical situations.
KW - Antiviral Agents
KW - DNA, Circular
KW - Drug Therapy, Combination
KW - Guanine
KW - Hepatitis B Surface Antigens
KW - Hepatitis B, Chronic
KW - Humans
KW - Interferon-alpha
KW - Polyethylene Glycols
KW - Recombinant Proteins
KW - Transcription, Genetic
KW - Viral Load
KW - Hepatitis B
U2 - 10.1111/liv.12720
DO - 10.1111/liv.12720
M3 - SCORING: Journal article
C2 - 25529096
VL - 35 Suppl 1
SP - 114
EP - 120
JO - LIVER INT
JF - LIVER INT
SN - 1478-3223
ER -
